---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-338068"
form_type: "8-K"
ticker: "SRZN"
cik: "0001824893"
company_name: "Surrozen, Inc./DE"
filed_at: "2026-08-06T20:15:55+00:00"
generated_at: "2026-08-06T20:19:46.852809+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Surrozen reports Q2 2026 results; IND for SZN-8141 planned by Q3 end; PTAB denies Merck petition

## Summary
- Planned IND submission for SZN-8141 in DME by end of Q3 2026; DUET Phase 1b/2a to start by year-end 2026 with initial data in H2 2027.
- PTAB denied Merck's post-grant review petition challenging Surrozen's U.S. Patent No. 12,297,278, reinforcing IP position.
- Boehringer Ingelheim milestone triggered $5.0M collaboration revenue in Q2 2026 (vs $0 in Q2 2025).
- Cash and cash equivalents $102.0M as of June 30, 2026, down from $106.9M as of March 31, 2026.
- Net income $50.2M (including $59.6M non-cash gains) vs $39.7M (including $47.6M non-cash gains) in Q2 2025.

## SEC filing metadata
- accession: 0001193125-26-338068
- form_type: 8-K
- ticker: SRZN
- cik: 0001824893
- company_name: Surrozen, Inc./DE
- filed_at: 2026-08-06T20:15:55+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1824893/000119312526338068/0001193125-26-338068-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1824893/000119312526338068/srzn-20260806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-338068
- JSON: https://secwatch.observer/filing/0001193125-26-338068.json
- Plain text: https://secwatch.observer/filing/0001193125-26-338068.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.